Infectious Disease · 2020
RECOVERY Trial: Dexamethasone for COVID-19
Randomised Evaluation of COVID-19 Therapy
In March 2020, as intensive care units across England filled with patients on mechanical ventilators, the University of Oxford launched a platform trial designed to test multiple COVID-19 treatments simultaneously within the NHS. RECOVERY (Randomised Evaluation of COVID-19 Therapy) opened across 176 hospitals, using an adaptive design that allowed arms to be added or dropped without closing the trial. Peter Horby and Martin Landray co-led the effort. Among the first agents tested was low-dose dexamethasone, a corticosteroid available at every hospital on earth, chosen because the pathophysiology of severe COVID-19 increasingly resembled a dysregulated inflammatory response rather than uncontrolled viral replication.
On June 16, 2020, investigators announced that 6 mg of dexamethasone daily for up to 10 days cut 28-day all-cause mortality from 25.7% to 22.9% in the overall population. The benefit was sharply concentrated by respiratory status. Among patients requiring invasive mechanical ventilation, the mortality reduction was 12.3 percentage points. Among those on supplemental oxygen alone, it was 4.2 percentage points. Patients receiving no respiratory support showed no benefit and a non-significant trend toward harm, a finding that argued against prophylactic steroid use in mild disease and indicated that the drug was treating the inflammatory injury, not the virus itself.
The WHO updated its clinical management guidance within hours of the announcement, before the formal paper appeared in the New England Journal of Medicine. That sequence, public health action preceding peer-reviewed publication, reflected the emergency conditions and the quality of the RECOVERY platform's design. Dexamethasone costs approximately five dollars per treatment course, placing it within reach of health systems at every income level. No logistical barrier stood between the evidence and its implementation.
RECOVERY continued enrolling into other arms after the dexamethasone result. Tocilizumab, an IL-6 receptor antagonist, and baricitinib, a JAK inhibitor, were subsequently shown to reduce mortality further in patients already receiving dexamethasone, establishing a layered anti-inflammatory strategy for severe COVID-19. The RECOVERY platform's design became a template cited in subsequent infectious disease preparedness discussions, valued for the speed at which it generated credible answers without sacrificing randomized controls.
Key People
- Peter Horby — Co-chief investigator, RECOVERY trial
- Martin Landray — Co-chief investigator, RECOVERY trial
- Richard Haynes — Senior trial manager, Oxford Population Health
- Jonathan Emberson — Senior statistician, Oxford Clinical Trial Service Unit
N Engl J Med. 2021;384(8):693-704 (preliminary report June 2020)
Related landmarks
- 2020 · BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) (Infectious Disease)
- 2020 · COVID-19 mRNA vaccine efficacy trials (Infectious Disease)
- 2017 · Ervebo (rVSV-ZEBOV) Ebola Vaccine: Ebola Ça Suffit! Ring Vaccination Trial (Infectious Disease)
- 2025 · Gepotidacin (Blujepa), first new oral antibiotic class in decades (Infectious Disease)